Expert Interview
Discussing the 52-week data from the SYNERGY-NASH Phase 2 trial presented at the EASL Congress of Eli Lilly's tirzepatide in patients with MASH
Ticker(s): LLYInstitution: Susquehanna Health
- specializes in gastroenterology and hepatology and is certified in gastroenterology by the American Board of Internal Medicine
- treats 120 patients for PBC
- familiar with the Phase 2 and Phase 3 ENHANCE studies of seladelpar in PBC
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
